# Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

> **NCT00295646** · PHASE3 · COMPLETED · sponsor: **Austrian Breast & Colorectal Cancer Study Group** · enrollment: 1803 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** tamoxifen
- **DRUG:** anastrozole
- **DRUG:** zoledronic acid
- **OTHER:** goserelin

## Key facts

- **NCT ID:** NCT00295646
- **Lead sponsor:** Austrian Breast & Colorectal Cancer Study Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06
- **Primary completion:** 2008-03-27
- **Final completion:** 2018-06-26
- **Target enrollment:** 1803 (ACTUAL)
- **Last updated:** 2024-03-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00295646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00295646, "Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00295646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*